{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T04:36:34Z","timestamp":1767414994259},"reference-count":18,"publisher":"Japanese Society of Internal Medicine","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,9,1]]},"DOI":"10.2169\/internalmedicine.8422-21","type":"journal-article","created":{"date-parts":[[2022,2,7]],"date-time":"2022-02-07T22:08:52Z","timestamp":1644271732000},"page":"2655-2660","source":"Crossref","is-referenced-by-count":2,"title":["Angioimmunoblastic T-cell Lymphoma Presenting as a Methotrexate-associated Lymphoproliferative Disorder with Extreme Peripheral Blood Plasmacytosis"],"prefix":"10.2169","volume":"61","author":[{"given":"Hiroyuki","family":"Murakami","sequence":"first","affiliation":[{"name":"Department of Hematology, National Hospital Organization Okayama Medical Center, Japan"},{"name":"Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Makita","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsunori","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Yoshioka","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keina","family":"Nagakita","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Shinno","sequence":"additional","affiliation":[{"name":"Department of Pathology, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadashi","family":"Yoshino","sequence":"additional","affiliation":[{"name":"Department of Pathology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Sunami","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Hospital Organization Okayama Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Gaulard P, Swerdlow SH, Harris NL, et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. IARC, Lyon, 2017: 462-444."},{"key":"2","doi-asserted-by":"publisher","unstructured":"2. Mariette X, Cazals-Hatem D, Warszawki J, et al. Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France. Blood 99: 3909-3915, 2002.","DOI":"10.1182\/blood.V99.11.3909"},{"key":"3","unstructured":"3. Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. J Rheumatol 34: 322-331, 2007."},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Kihara R, Watanabe T, Yano T, et al. Prognosis of mature T cell lymphoma is poorer than that of diffuse large B cell lymphoma in IPI low-risk group, but not in intermediate- and high-risk groups. Int J Hematol 97: 98-102, 2013.","DOI":"10.1007\/s12185-012-1243-2"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Dogan A, Attygalle AD, Kyriakou C. Angioimmunoblastic T-cell lymphoma. Br J Haematol 121: 681-691, 2003.","DOI":"10.1046\/j.1365-2141.2003.04335.x"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Armitage JO. The aggressive peripheral T-cell lymphomas: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 87: 511-519, 2012.","DOI":"10.1002\/ajh.23144"},{"key":"7","doi-asserted-by":"publisher","unstructured":"7. Tokunaga T, Shimada K, Yamamoto K, et al. Retrospective analysis of prognostic factors for angioimmunoblastic T-cell lymphoma: a multicenter cooperative study in Japan. Blood 119: 2837-2843, 2012.","DOI":"10.1182\/blood-2011-08-374371"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8. Mourad N, Mounier N, Bri\u00e8re J, et al. Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. Blood 111: 4463-4470, 2008.","DOI":"10.1182\/blood-2007-08-105759"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood 115: 1026-1036, 2010.","DOI":"10.1182\/blood-2009-06-227579"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hsu SM, Waldron JA, Fink L, et al. Pathogenic significance of interleukin-6 in angioimmunoblastic lymphadenopathy-type T-cell lymphoma. Hum Pathol 24: 126-131, 1993.","DOI":"10.1016\/0046-8177(93)90290-W"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Grogg KL, Morice WG, Macon WR. Spectrum of bone marrow findings in patients with angioimmunoblastic T-cell lymphoma. Br J Haematol 137: 416-422, 2007.","DOI":"10.1111\/j.1365-2141.2007.06577.x"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Dupuis J, Boye K, Martin N, et al. Expression of CXCL13 by neoplastic cells in angioimmunoblastic T-cell lymphoma (AITL): a new diagnostic marker providing evidence that AITL derives from follicular helper T cells. Am J Surg Pathol 30: 490-494, 2006.","DOI":"10.1097\/00000478-200604000-00009"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Hatanaka K, Nakamura N, Kojima M, et al. Methotrexate-associated lymphoproliferative disorders mimicking angioimmunoblastic T-cell lymphoma. Pathol Res Pract 206: 9-13, 2010.","DOI":"10.1016\/j.prp.2009.03.005"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Satou A, Tabata T, Miyoshi H, et al. Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases. Mod Pathol 32: 1135-1146, 2019.","DOI":"10.1038\/s41379-019-0264-2"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Sokol K, Kartan S, Johnson WT, et al. Extreme peripheral blood plasmacytosis mimicking plasma cell leukemia as a presenting feature of angioimmunoblastic T-cell lymphoma (AITL). Front Oncol 9: 509, 2019.","DOI":"10.3389\/fonc.2019.00509"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Nagoshi H, Kuroda J, Kobayashi T, et al. Clinical manifestation of angioimmunoblastic T-cell lymphoma with exuberant plasmacytosis. Int J Hematol 98: 366-374, 2013.","DOI":"10.1007\/s12185-013-1411-z"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Tokuhira M, Saito S, Okuyama A, et al. Clinicopathologic investigation of methotrexate-induced lymphoproliferative disorders, with a focus on regression. Leuk Lymphoma 59: 1143-1152, 2018.","DOI":"10.1080\/10428194.2017.1369073"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tokuhira M, Tanaka Y, Takahashi Y, et al. The clinical impact of absolute lymphocyte count in peripheral blood among patients with methotrexate-associated lymphoproliferative disorders. J Clin Exp Hematop 60: 41-50, 2020.","DOI":"10.3960\/jslrt.19039"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/17\/61_8422-21\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T05:19:23Z","timestamp":1715231963000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/17\/61_8422-21\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,1]]},"references-count":18,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.8422-21","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,1]]},"article-number":"8422-21"}}